| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
76,123 |
69,942 |
$5.08M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
52,150 |
42,338 |
$3.06M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
33,320 |
31,983 |
$2.83M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
34,194 |
33,984 |
$2.41M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
30,396 |
30,272 |
$2.41M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
13,988 |
13,972 |
$1.57M |
| S9083 |
Global fee urgent care centers |
26,407 |
22,378 |
$1.10M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
19,287 |
14,334 |
$836K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
24,271 |
20,895 |
$792K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
28,104 |
24,097 |
$780K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
16,314 |
13,223 |
$591K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,374 |
4,071 |
$307K |
| 99201 |
|
3,415 |
3,407 |
$203K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
14,898 |
9,501 |
$184K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
47,849 |
45,740 |
$164K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
4,370 |
4,065 |
$97K |
| 87081 |
|
11,709 |
11,313 |
$60K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,261 |
1,248 |
$14K |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
1,928 |
1,441 |
$13K |
| 0011A |
|
194 |
191 |
$8K |
| 0012A |
|
174 |
171 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
9,612 |
9,437 |
$7K |
| 90756 |
|
253 |
253 |
$6K |
| 90688 |
|
347 |
347 |
$6K |
| 90686 |
|
201 |
199 |
$3K |
| 81002 |
|
1,861 |
1,789 |
$3K |
| 86328 |
|
95 |
92 |
$3K |
| 81000 |
|
841 |
829 |
$3K |
| 12001 |
|
27 |
27 |
$2K |
| 87070 |
|
386 |
381 |
$2K |
| 99000 |
|
1,761 |
1,640 |
$1K |
| 81025 |
|
354 |
349 |
$910.67 |
| 73110 |
|
38 |
38 |
$888.44 |
| 73630 |
|
37 |
37 |
$751.84 |
| 71045 |
Radiologic examination, chest; single view |
38 |
38 |
$541.48 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
38 |
38 |
$516.41 |
| 69210 |
|
13 |
12 |
$484.10 |
| 73140 |
|
16 |
16 |
$341.53 |
| 86480 |
|
14 |
13 |
$330.00 |
| 85018 |
|
129 |
129 |
$252.99 |
| 87186 |
|
27 |
26 |
$124.52 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
12 |
12 |
$67.43 |
| 85048 |
|
17 |
17 |
$53.89 |
| 99051 |
|
27 |
26 |
$16.07 |
| 99080 |
|
235 |
136 |
$0.00 |